{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:25:59Z","timestamp":1792477559244,"version":"4.5.0"},"reference-count":299,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.jaad.2008.01.001","type":"journal-article","created":{"date-parts":[[2008,3,15]],"date-time":"2008-03-15T10:55:14Z","timestamp":1205578514000},"page":"545-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":199,"title":["Chemotherapeutic agents and the skin: An update"],"prefix":"10.1016","volume":"58","author":[{"given":"Noushin","family":"Heidary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Burgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2008.01.001_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0190-9622(99)70488-3","article-title":"Mucocutaneous reactions to chemotherapy","volume":"40","author":"Susser","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1568011043482106","article-title":"Epidermal growth factor receptor inhibitors: A new prospective in the treatment of lung cancer","volume":"4","author":"Tiseo","year":"2004","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10.1016\/j.jaad.2008.01.001_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.bjc.6601550","article-title":"Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors","volume":"90","author":"Blackledge","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib4","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","article-title":"Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor","volume":"147","author":"Van Doorn","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib6","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib7","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2008.01.001_bib8","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2003.10.051","article-title":"Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"21","author":"Cohen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11 suppl. 12","key":"10.1016\/j.jaad.2008.01.001_bib9","first-page":"23","article-title":"Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome?","volume":"17","author":"Perez-Soler","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2008.01.001_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","article-title":"Monoclonal antibodies as therapeutic agents for cancer","volume":"5","author":"Harris","year":"2004","journal-title":"Lancet Oncol"},{"issue":"5 suppl. 14","key":"10.1016\/j.jaad.2008.01.001_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/sonc.2002.35648","article-title":"Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody","volume":"29","author":"Needle","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2003.10.003","article-title":"Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation","volume":"30","author":"Thomas","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaad.2008.01.001_bib13","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2230.2004.01466.x","article-title":"Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor","volume":"29","author":"Fernandez-Galar","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","article-title":"Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours","volume":"151","author":"Jacot","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib19","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and\u00a0management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients","volume":"55","author":"Roe","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: Clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.138.1.129","article-title":"Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors","volume":"2138","author":"Kimyai-Asadi","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib23","first-page":"1397","article-title":"Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody","volume":"12","author":"Wu","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2008.01.001_bib24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1503\/cmaj.1040795","article-title":"A man whose scapula was spared a drug-associated rash","volume":"172","author":"Sanz","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.jaad.2008.01.001_bib25","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1200\/JCO.2005.05.1631","article-title":"Erlotinib induced skin rash spares skin in previous radiotherapy field","volume":"24","author":"Mitra","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaad.2006.06.034","article-title":"Treatment of gefitinib-associated folliculitis","volume":"55","author":"Matheis","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000088502","article-title":"Cetuximab-induced acne","volume":"211","author":"Molinari","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.01.001_bib28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2133.2005.06835.x","article-title":"Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy","volume":"153","author":"Gutzmer","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archderm.141.9.1173","article-title":"Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy","volume":"141","author":"Micantonio","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib30","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: Is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib31","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non\u2013small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.jaad.2008.01.001_bib33","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0959-8049(01)00233-7","article-title":"The EGFR as a target for anticancer therapy\u2014Focus on cetuximab","volume":"37","author":"Baselga","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib35","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1200\/JCO.2004.08.189","article-title":"Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor","volume":"22","author":"Tan","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib36","first-page":"226a","article-title":"Cetuximab (C225) plus cisplatin\/carboplatin is active in patients (pts) with recurrent\/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen (abstract)","volume":"21","author":"Baselga","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib37","first-page":"232A","volume":"21","author":"Kies","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib38","unstructured":"Saltz L, Rubin MS, Hochster H. Acne-like rash predicts response in patients treated with Cetuximab (IMC-C225) plus Irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). In: American Association for Cancer Research\/National Cancer Institute\/European Organization for Research and Treatment of Cancer International Conference; 2001."},{"key":"10.1016\/j.jaad.2008.01.001_bib39","first-page":"622","article-title":"A randomized placebo-controlled trial of erlotinib in patients with advanced nonsmall cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial (abstract)","volume":"23","author":"Shepherd","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib40","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/dji104","article-title":"Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient","volume":"97","author":"Tonini","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2008.01.001_bib41","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000073100","article-title":"Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor","volume":"207","author":"Dainichi","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.01.001_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1346-8138.2003.tb00387.x","article-title":"Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor","volume":"30","author":"Nakano","year":"2003","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib45","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2002.124621","article-title":"Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody","volume":"47","author":"Boucher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib46","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1200\/JCO.2003.04.169","article-title":"Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab","volume":"21","author":"Monti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2005.07010.x","article-title":"Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab","volume":"154","author":"Shu","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaad.2005.12.016","article-title":"Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib","volume":"55","author":"Graves","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib49","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1200\/JCO.2005.01.9570","article-title":"Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab","volume":"23","author":"Montagut","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib50","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"16","author":"Bouche","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/02841860310006038","article-title":"Epidermal growth factor receptor inhibition induces trichomegaly","volume":"42","author":"Dueland","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib52","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2004.06265.x","article-title":"Trichomegaly following treatment with gefitinib (ZD1839)","volume":"151","author":"Pascual","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib53","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2230.2006.02223.x","article-title":"Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor","volume":"31","author":"Lacouture","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib54","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clinthera.2005.06.003","article-title":"Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer","volume":"27","author":"Wong","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2008.01.001_bib55","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: Panitumumab (Vectibix)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncologist"},{"issue":"4 suppl. 4","key":"10.1016\/j.jaad.2008.01.001_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/sonu.2002.37407","article-title":"The epidermal growth factor receptor as a novel target for cancer therapy: Case studies and clinical implications","volume":"18","author":"Riddle","year":"2002","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.jaad.2008.01.001_bib57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-4632.2005.02185.x","article-title":"Purpuric drug eruption possibly due to gefinitib (Iressa)","volume":"44","author":"Kurokawa","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib58","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/00015550410024634","article-title":"Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor","volume":"84","author":"Zorzou","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4414\/smw.2003.10117","article-title":"Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition","volume":"133","author":"Trojan","year":"2003","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.jaad.2008.01.001_bib60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000092836","article-title":"Grover's disease induced by cetuximab","volume":"213","author":"Tscharner","year":"2006","journal-title":"Dermatology"},{"issue":"2 suppl. 6","key":"10.1016\/j.jaad.2008.01.001_bib61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.seminoncol.2004.03.038","article-title":"Molecularly targeted treatment for dermatofibrosarcoma protuberans","volume":"31","author":"McArthur","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib62","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and\u00a0FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib63","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib64","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1200\/JCO.2005.06.079","article-title":"Imatinib-induced regression of AIDS-related Kaposi's sarcoma","volume":"23","author":"Koon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000085561","article-title":"Systemic mastocytosis: Bone marrow pathology, classification, and current therapies","volume":"114","author":"Pardanani","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib66","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.0022-202X.2004.22231.x","article-title":"Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo","volume":"122","author":"McGary","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib67","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/cncr.21834","article-title":"Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy","volume":"106","author":"Wyman","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib68","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib69","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2008.01.001_bib70","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib71","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.2003.04151_4.x","article-title":"A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec)","volume":"120","author":"Drummond","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib72","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A\u00a0prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib73","first-page":"2929","article-title":"Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors","volume":"61","author":"Pietras","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib74","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/sj.eye.6701315","article-title":"Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)","volume":"18","author":"Esmaeli","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.jaad.2008.01.001_bib75","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2403364","article-title":"Visual disturbance due to retinal edema as a complication of imatinib","volume":"18","author":"Kusumi","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2008.01.001_bib76","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2141.2002.03499.x","article-title":"Stevens\u2013Johnson syndrome after treatment with STI571: A case report","volume":"117","author":"Hsiao","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib77","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2002-08-2431","article-title":"Managing cutaneous reactions to imatinib therapy","volume":"100","author":"Rule","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2008.01.001_bib78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1345\/aph.1E127","article-title":"Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors","volume":"39","author":"Severino","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2008.01.001_bib79","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1365-2141.2002.37133.x","article-title":"Sti571-induced Stevens\u2013Johnson syndrome","volume":"119","author":"Vidal","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib80","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0378-6323.16628","article-title":"Imatinib induced Stevens\u2013Johnson syndrome: Lack of recurrence following re-challenge with a lower dose","volume":"71","author":"Pavithran","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2008.01.001_bib81","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2002-12-3696","article-title":"Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia","volume":"101","author":"Sanchez-Gonzalez","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2008.01.001_bib82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000051705","article-title":"Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia","volume":"203","author":"Brouard","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.01.001_bib83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1034\/j.1600-0609.2002.02830.x","article-title":"Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia","volume":"69","author":"Schwarz","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib84","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000088510","article-title":"Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia","volume":"211","author":"Gambillara","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.01.001_bib85","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1200\/JCO.2002.20.3.869","article-title":"Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571","volume":"20","author":"Raanani","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib86","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib87","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib88","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/cncr.20267","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"100","author":"Leong","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib89","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2141.2005.05431.x","article-title":"Loss of skin pigment caused by imatinib therapy","volume":"129","author":"McPartlin","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib90","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.1365-2141.2003.04208_3.x","article-title":"Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate","volume":"120","author":"Rousselot","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib91","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2133.2005.06813.x","article-title":"Imatinib mesilate (Glivec): A\u00a0systemic depigmenting agent for extensive vitiligo?","volume":"153","author":"Legros","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib92","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1523-1747.1998.00272.x","article-title":"The SCF\/KIT pathway plays a critical role in the control of normal human\u00a0melanocyte homeostasis","volume":"111","author":"Grichnik","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib93","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJM200208083470614","article-title":"Imatinib mesylate and gray hair","volume":"347","author":"Etienne","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib94","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0378-6323.19727","article-title":"Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia","volume":"72","author":"Prabhash","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2008.01.001_bib95","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/j.1365-2133.2006.07276.x","article-title":"Imatinib-associated lichenoid eruption: Acitretin treatment allows maintained antineoplastic effect","volume":"154","author":"Dalmau","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib96","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/09546630410015556","article-title":"Oral lichenoid eruption secondary to imatinib (Glivec)","volume":"15","author":"Ena","year":"2004","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2008.01.001_bib97","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.10105","article-title":"Lichenoid eruption to STI 571","volume":"70","author":"Lim","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib98","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000063899","article-title":"Oral lichenoid reaction to imatinib (STI 571, Gleevec)","volume":"205","author":"Lim","year":"2002","journal-title":"Dermatology"},{"issue":"6-7 pt 1","key":"10.1016\/j.jaad.2008.01.001_bib99","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0151-9638(04)93669-1","article-title":"Lichenoid cutaneous reaction to imatinib","volume":"131","author":"Roux","year":"2004","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.0303-6987.2003.053.x","article-title":"Mycosis fungoides-like reaction in a patient treated with Gleevec","volume":"30","author":"Clark","year":"2003","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2008.01.001_bib101","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(05)70322-3","article-title":"Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: Role of a T-cell clone induced by imatinib","volume":"6","author":"Jardin","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib102","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1365-2133.2004.06295.x","article-title":"Follicular mucinosis associated with imatinib (STI571)","volume":"151","author":"Yanagi","year":"2004","journal-title":"Br J Dermatol"},{"issue":"5 suppl. 1","key":"10.1016\/j.jaad.2008.01.001_bib103","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/j.jaad.2004.10.888","article-title":"Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases","volume":"53","author":"Brazzelli","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib104","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00015550310012593","article-title":"Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate","volume":"83","author":"Pasmatzi","year":"2003","journal-title":"Acta Derm Venereol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2008.01.001_bib105","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0145-2126(03)00257-1","article-title":"Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate","volume":"28","author":"Liu","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib106","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archderm.141.3.368","article-title":"Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia","volume":"141","author":"Ayirookuzhi","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib107","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.leukres.2004.05.015","article-title":"Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy","volume":"29","author":"Dib","year":"2005","journal-title":"Leuk Res"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2008.01.001_bib108","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaad.2005.12.011","article-title":"Imatinib-induced eccrine squamous syringometaplasia","volume":"55","author":"Van de Voorde","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000073102","article-title":"Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign","volume":"207","author":"Banka","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.01.001_bib110","first-page":"1152","article-title":"Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia","volume":"46","author":"Shimizu","year":"2005","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.jaad.2008.01.001_bib111","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1365-2133.2006.07262.x","article-title":"Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia","volume":"154","author":"Deguchi","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib112","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/sj.leu.2403115","article-title":"Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia","volume":"18","author":"Breccia","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2008.01.001_bib113","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2003-07-2436","article-title":"EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate","volume":"102","author":"Bekkenk","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2008.01.001_bib114","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib115","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance","volume":"102","author":"Burgess","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2008.01.001_bib116","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cncr.22881","article-title":"Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia","volume":"110","author":"Piccaluga","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib117","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"Nnilotinib: A novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib118","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib119","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2008.01.001_bib120","unstructured":"Sprycel package insert. Bristol-Meyers Squibb, New York, NY.\u00a0Available from: http:\/\/www.fda.gov\/cder\/foi\/label\/2006\/021986lbl.pdf [Accessed January 6, 2008]."},{"key":"10.1016\/j.jaad.2008.01.001_bib121","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1056\/NEJMc053425","article-title":"Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia","volume":"354","author":"Assouline","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib122","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1080\/10428190600555868","article-title":"Dasatinib-related alveolar pneumonia responsive to corticosteroids","volume":"47","author":"Radaelli","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2008.01.001_bib123","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib124","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2008.01.001_bib125","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1128\/MCB.19.8.5308","article-title":"B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK\/Erk pathway","volume":"19","author":"Erhardt","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jaad.2008.01.001_bib126","first-page":"81","article-title":"Analysis of the transcriptional program induced by Raf in epithelial cells","volume":"159","author":"Schulze","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.jaad.2008.01.001_bib127","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1038\/sj.onc.1204614","article-title":"Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria","volume":"20","author":"Zhong","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2008.01.001_bib128","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib129","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.cco.0000245316.82391.52","article-title":"Sorafenib","volume":"18","author":"Hahn","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.5414\/CPP42650","article-title":"Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer","volume":"42","author":"Richly","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jaad.2008.01.001_bib131","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bjc.6603291","article-title":"Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis","volume":"95","author":"Eisen","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib132","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","article-title":"Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer","volume":"12","author":"Siu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib133","first-page":"188","article-title":"Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer","volume":"5","author":"Kupsch","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib134","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","article-title":"Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors","volume":"11","author":"Clark","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib135","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/annonc\/mdl017","article-title":"Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors","volume":"17","author":"Richly","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib136","doi-asserted-by":"crossref","first-page":"580","DOI":"10.5414\/CPP40580","article-title":"Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors","volume":"40","author":"Strumberg","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jaad.2008.01.001_bib137","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib138","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1200\/JCO.2005.12.017","article-title":"Angiogenesis of breast cancer","volume":"23","author":"Schneider","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib139","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2008.01.001_bib140","first-page":"5465","article-title":"An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients","volume":"9","author":"O'Farrell","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib141","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1210\/jc.2005-2845","article-title":"An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET\/papillary thyroid cancer kinases","volume":"91","author":"Kim","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2008.01.001_bib142","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib143","first-page":"765a","article-title":"Phase I trial of SU11248, a novel tyrosine kinase inhibitor in advanced solid tumors (abstract)","volume":"22","author":"Rosen","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib144","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-143-4-200508160-00021","article-title":"Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors?","volume":"143","author":"Robert","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib146","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2006.06.030","article-title":"Pleomophic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma","volume":"55","author":"Wu","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib147","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2141.2006.06201.x","article-title":"Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response?","volume":"134","author":"Gerecitano","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib148","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2141.2005.05636.x","article-title":"Bortezomib-induced Sweet syndrome","volume":"131","author":"Knoops","year":"2005","journal-title":"Br J Haematol"},{"issue":"suppl 12","key":"10.1016\/j.jaad.2008.01.001_bib149","article-title":"Bortezomib-induced Sweet's s\u00edndrome","volume":"90","author":"Van Regenmortel","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jaad.2008.01.001_bib150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000094689","article-title":"Bortezomib-induced skin lesion","volume":"116","author":"Ozcan","year":"2006","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.jaad.2008.01.001_bib151","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1470-2045(06)70944-5","article-title":"Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma","volume":"7","author":"Ramadan","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib152","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/1097-0142(19950701)76:1<110::AID-CNCR2820760117>3.0.CO;2-9","article-title":"Docetaxel (Taxotere) associated scleroderma-like changes of the\u00a0lower extremities. A report of three cases","volume":"76","author":"Battafarano","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib153","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0305-7372(03)00116-6","article-title":"Classification of anticancer drugs\u2014A new system based on therapeutic targets","volume":"29","author":"Espinosa","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaad.2008.01.001_bib154","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","article-title":"Docetaxel","volume":"13","author":"Cortes","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib155","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/archderm.1995.01690140086015","article-title":"Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent","volume":"131","author":"Zimmerman","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib156","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1346-8138.2004.tb00692.x","article-title":"A case of docetaxel-induced erythrodysesthesia","volume":"31","author":"Katoh","year":"2004","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib157","first-page":"1161","article-title":"Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine","volume":"18","author":"Scheithauer","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2008.01.001_bib158","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.coc.0000026486.56886.18","article-title":"Cutaneous hand and foot toxicity associated with cancer chemotherapy","volume":"26","author":"Childress","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib159","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archderm.139.1.77","article-title":"Cutaneous reactions to chemotherapy drugs: The art of consultation","volume":"139","author":"Remlinger","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand-foot\u2019) syndrome. Incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib161","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00000421-200212000-00015","article-title":"Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer","volume":"25","author":"Eich","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib162","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1046\/j.1365-2133.2002.45481.x","article-title":"Squamous syringometaplasia associated with docetaxel","volume":"146","author":"Karam","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib163","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jnci\/86.7.557","article-title":"Prevention of docetaxel-induced erythrodysesthesia with local hypothermia","volume":"86","author":"Zimmerman","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2008.01.001_bib164","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1046\/j.1365-2133.2000.03432.x","article-title":"Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel","volume":"142","author":"Chu","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3904\/kjim.2004.19.2.132","article-title":"Nail changes during docetaxel containing combination chemotherapy","volume":"19","author":"Woo","year":"2004","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jaad.2008.01.001_bib166","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000018132","article-title":"Nail changes secondary to docetaxel (Taxotere)","volume":"198","author":"Correia","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.01.001_bib167","first-page":"1037","article-title":"Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion","volume":"53","author":"Extra","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib168","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1078::AID-CNCR19>3.0.CO;2-T","article-title":"Cutaneous fibrosis induced by docetaxel: A case report","volume":"88","author":"Cleveland","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib169","first-page":"197","article-title":"Scleroderma in association with the use of docetaxel (taxotere) for breast cancer","volume":"19","author":"Hassett","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib170","first-page":"818","article-title":"Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: Report of 4 cases","volume":"31","author":"Chen","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib171","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00000637-200045040-00016","article-title":"Docetaxel (taxotere) extravasation: A report of five cases with treatment recommendations","volume":"45","author":"Ascherman","year":"2000","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.jaad.2008.01.001_bib172","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/00015550310013079","article-title":"Vesicant-type reaction due to docetaxel extravasation","volume":"83","author":"Ho","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib173","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0305-7372(93)90010-O","article-title":"The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere)","volume":"19","author":"Pazdur","year":"1993","journal-title":"Cancer Treat Rev"},{"issue":"4 suppl. 3","key":"10.1016\/j.jaad.2008.01.001_bib174","first-page":"1","article-title":"Clinical toxicities encountered with paclitaxel (Taxol)","volume":"20","author":"Rowinsky","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib175","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.1994.12.2.439","article-title":"Paclitaxel and radiation-recall dermatitis","volume":"12","author":"Shenkier","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib176","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.annonc.a010730","article-title":"Paclitaxel-induced radiation recall dermatitis","volume":"7","author":"Bokemeyer","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib177","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/(SICI)1096-911X(199609)27:3<185::AID-MPO9>3.0.CO;2-A","article-title":"Paclitaxel-induced radiation recall dermatitis","volume":"27","author":"McCarty","year":"1996","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib178","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00007611-199605000-00022","article-title":"Paclitaxel: Severe mucocutaneous toxicity in a patient with hyperbilirubinemia","volume":"89","author":"Payne","year":"1996","journal-title":"South Med J"},{"key":"10.1016\/j.jaad.2008.01.001_bib179","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00873811","article-title":"Cutaneous manifestations of Taxol therapy","volume":"13","author":"Link","year":"1995","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2008.01.001_bib180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000246419","article-title":"Taxol-induced acral erythema","volume":"192","author":"de Argila","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2008.01.001_bib181","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-4362.1997.tb01164.x","article-title":"Generalized pustular dermatosis following paclitaxel therapy","volume":"36","author":"Weinberg","year":"1997","journal-title":"Int J Dermatol"},{"issue":"2 pt 1","key":"10.1016\/j.jaad.2008.01.001_bib182","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0190-9622(96)80147-2","article-title":"Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption","volume":"34","author":"Young","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib183","first-page":"167","article-title":"Inflammatory actinic keratoses secondary to systemic chemotherapy","volume":"75","author":"Ilyas","year":"2005","journal-title":"Cutis"},{"issue":"2C","key":"10.1016\/j.jaad.2008.01.001_bib184","first-page":"1135","article-title":"Stevens\u2013Johnson syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: A case report","volume":"24","author":"Hiraki","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546630510026724","article-title":"Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins","volume":"16","author":"Cohen","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2008.01.001_bib186","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mjd.2003.30","article-title":"Scleroderma-like cutaneous lesions induced by paclitaxel: A case study","volume":"48","author":"Kupfer","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib187","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","article-title":"Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy","volume":"11","author":"Fumoleau","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib188","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<965::AID-CNCR23>3.0.CO;2-Y","article-title":"Hand-foot syndrome following prolonged infusion of high doses of vinorelbine","volume":"82","author":"Hoff","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib189","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1468-3083.2002.00564.x","article-title":"Skin necrosis from extravasation of vinorelbine","volume":"16","author":"Moreno de Vega","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib190","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/030089160008600406","article-title":"Two case reports of vinorelbine extravasation: Management and review of the literature","volume":"86","author":"Cicchetti","year":"2000","journal-title":"Tumori"},{"key":"10.1016\/j.jaad.2008.01.001_bib191","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0268-960X(94)90072-P","article-title":"The role of fludarabine in hematological malignancies","volume":"8","author":"Wright","year":"1994","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaad.2008.01.001_bib192","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/106002809102500512","article-title":"Fludarabine: A review","volume":"25","author":"Hood","year":"1991","journal-title":"DICP"},{"key":"10.1016\/j.jaad.2008.01.001_bib193","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0277-5379(85)90283-4","article-title":"Phase I study of fludarabine (2-fluoro-ara-AMP)","volume":"21","author":"Kavanagh","year":"1985","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib194","first-page":"92","article-title":"Peculiar acral erythematous eruption after fludarabine treatment","volume":"17","author":"Nomdedeu","year":"1995","journal-title":"Biol Clin Hematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib195","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2004.05.012","article-title":"Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia","volume":"22","author":"Rossi","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib196","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/jcp.47.6.541","article-title":"Diagnostic features of transfusion associated graft versus host disease","volume":"47","author":"Appleton","year":"1994","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jaad.2008.01.001_bib197","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s002770050347","article-title":"Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL)","volume":"75","author":"Braess","year":"1997","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib198","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.1995.tb05311.x","article-title":"Diagnosis of transfusion-associated graft-versus-host disease\u00a0by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia","volume":"91","author":"Briz","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib199","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2141.1994.tb05093.x","article-title":"Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia","volume":"88","author":"Maung","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib200","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/oxfordjournals.annonc.a059294","article-title":"Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine","volume":"6","author":"Bazarbachi","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib201","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1468-3083.2004.00917.x","article-title":"Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans","volume":"18","author":"Powell","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib202","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1046\/j.1365-2133.2001.04244.x","article-title":"Paraneoplastic pemphigus: An association with fludarabine?","volume":"144","author":"Gooptu","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib203","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/oxfordjournals.annonc.a059209","article-title":"Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias","volume":"6","author":"Pott-Hoeck","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib204","first-page":"77","article-title":"Paraneoplastic pemphigus","volume":"12","author":"Anhalt","year":"1997","journal-title":"Adv Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib205","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<957::AID-CNCR22>3.0.CO;2-Z","article-title":"Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma","volume":"82","author":"Kong","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib206","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04506.x","article-title":"Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol","volume":"122","author":"Chubar","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib207","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2257.2000.00283.x","article-title":"Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution","volume":"22","author":"Grey","year":"2000","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.jaad.2008.01.001_bib208","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2340\/0001555576385386","article-title":"Cutaneous reactions after treatment with 2-chlorodeoxyadenosine","volume":"76","author":"Meunier","year":"1996","journal-title":"Acta Derm Venereol"},{"issue":"3 suppl. 6","key":"10.1016\/j.jaad.2008.01.001_bib209","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0093-7754(03)00135-0","article-title":"Practical considerations in the use of oral fluoropyrimidines","volume":"30","author":"Hoff","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib210","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1634\/theoncologist.7-4-288","article-title":"Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review","volume":"7","author":"Malet-Martino","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2008.01.001_bib211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1081\/CNV-120000360","article-title":"Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience","volume":"20","author":"Abushullaih","year":"2002","journal-title":"Cancer Invest"},{"key":"10.1016\/j.jaad.2008.01.001_bib212","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.breast.2005.07.007","article-title":"Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction","volume":"15","author":"Kara","year":"2006","journal-title":"Breast"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2008.01.001_bib213","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ejon.2004.06.007","article-title":"Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)","volume":"8","author":"Lassere","year":"2004","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.jaad.2008.01.001_bib214","first-page":"101","article-title":"Serious hand-and-foot syndrome in black patients treated with capecitabine: Report of 3 cases and review of the literature","volume":"73","author":"Narasimhan","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2008.01.001_bib215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1188\/05.CJON.103-106","article-title":"Palmar-plantar erythrodysesthesia","volume":"9","author":"Wilkes","year":"2005","journal-title":"Clin J Oncol Nurs"},{"issue":"6","key":"10.1016\/j.jaad.2008.01.001_bib216","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1046\/j.1365-2133.2002.05000_6.x","article-title":"Pyogenic granuloma-like lesions during capecitabine therapy","volume":"147","author":"Piguet","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib217","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/archderm.140.3.367","article-title":"Inflammation of actinic keratoses during capecitabine therapy","volume":"140","author":"Lewis","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib218","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(01)06650-8","article-title":"Clinical picture: Leopard-like vitiligo with capecitabine","volume":"358","author":"Schmid-Wendtner","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.01.001_bib219","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2133.2001.04391.x","article-title":"Onychomadesis and onycholysis associated with capecitabine","volume":"145","author":"Chen","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib220","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2340\/00015555777273","article-title":"Chemotherapy-induced acral erythema due to Tegafur","volume":"77","author":"Bastida","year":"1997","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib221","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jjco\/hye032","article-title":"Case report: Hand-foot syndrome induced by the oral fluoropyrimidine S-1","volume":"31","author":"Elasmar","year":"2001","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib222","first-page":"165","article-title":"Cutaneous toxicity by ftorafur, hand-foot or palmar-plantar erythrodysesthesia syndrome","volume":"188","author":"Camps","year":"1991","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.jaad.2008.01.001_bib223","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/archderm.1995.01690150130035","article-title":"Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur","volume":"131","author":"Jucgla","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib224","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2340\/00015555778081","article-title":"Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur","volume":"77","author":"Rios-Buceta","year":"1997","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib225","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-4362.1998.00346.x","article-title":"Knuckle pad-like keratoderma: A new cutaneous side reaction induced by tegafur","volume":"37","author":"Won","year":"1998","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib226","first-page":"955","article-title":"Cutaneous side-effects caused by Tegafur","volume":"38","author":"Revenga","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib227","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/00015550310007715","article-title":"Black lunula caused by Tegafur","volume":"84","author":"Chen","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib228","first-page":"205","article-title":"Tegafur-induced acral hyperpigmentation","volume":"48","author":"Llistosella","year":"1991","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2008.01.001_bib229","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-4362.1997.00219.x","article-title":"Tegafur-induced photosensitivity\u2014Evaluation of provocation by UVB irradiation","volume":"36","author":"Usuki","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib230","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1346-8138.1999.tb03448.x","article-title":"Mucha\u2013Habermann disease-like eruptions due to Tegafur","volume":"26","author":"Kawamura","year":"1999","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib231","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1006327729228","article-title":"Gemcitabine in non-small cell lung cancer (NSCLC)","volume":"18","author":"Manegold","year":"2000","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2008.01.001_bib232","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/cncr.10602","article-title":"Phase II trial of gemcitabine in advanced sarcomas","volume":"94","author":"Okuno","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib233","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000069315","article-title":"Role of gemcitabine in the treatment of advanced and metastatic breast cancer","volume":"64","author":"Heinemann","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.jaad.2008.01.001_bib234","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/000155501317208381","article-title":"Gemcitabine-induced acute lipodermatosclerosis-like reaction","volume":"81","author":"Chu","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib235","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/030089160108700614","article-title":"Gemcitabine-induced radiation recall dermatitis: Case report","volume":"87","author":"Bar-Sela","year":"2001","journal-title":"Tumori"},{"key":"10.1016\/j.jaad.2008.01.001_bib236","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.2000.18.3.693","article-title":"Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine","volume":"18","author":"Burstein","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib237","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1200\/JCO.2000.18.3.695","article-title":"Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine","volume":"18","author":"Castellano","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib238","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0090-8258(03)00404-9","article-title":"Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy","volume":"91","author":"Schwartz","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib239","first-page":"306","article-title":"Gemcitabine-induced rectus abdominus radiation recall","volume":"7","author":"Fakih","year":"2006","journal-title":"JOP"},{"key":"10.1016\/j.jaad.2008.01.001_bib240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0169-5002(01)00194-5","article-title":"Radiation recall reaction following gemcitabine","volume":"33","author":"Fogarty","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib241","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0360-3016(02)02773-6","article-title":"Gemcitabine-induced radiation recall","volume":"53","author":"Jeter","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jaad.2008.01.001_bib242","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1345\/aph.10268","article-title":"Linear immunoglobulin A bullous dermatosis induced by gemcitabine","volume":"35","author":"del Pozo","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2008.01.001_bib243","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaad.2001.07.001","article-title":"Gemcitabine-associated scleroderma-like changes of the lower extremities","volume":"51","author":"Bessis","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib244","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1468-3083.2006.01535.x","article-title":"Erysipeloid skin toxicity induced by gemcitabine","volume":"20","author":"Zustovich","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00001813-200001000-00003","article-title":"Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine\u2014A report of three cases","volume":"11","author":"Brandes","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jaad.2008.01.001_bib246","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1468-3083.2002.00485.x","article-title":"Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma","volume":"16","author":"Kuku","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib247","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1046\/j.1365-2133.2001.t01-1-04461.x","article-title":"Gemcitabine-associated CD8+ CD30+ pseudolymphoma","volume":"145","author":"Marucci","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib248","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00001813-200309000-00012","article-title":"Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine","volume":"14","author":"Sommers","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jaad.2008.01.001_bib249","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/00015550252948275","article-title":"Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment","volume":"82","author":"Chu","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.01.001_bib250","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/A:1025480914273","article-title":"A phase II trial of pemetrexed in patients with metastatic renal cancer","volume":"21","author":"Thodtmann","year":"2003","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2008.01.001_bib251","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2000.18.8.1748","article-title":"Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors","volume":"18","author":"Adjei","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib252","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.10-6-363","article-title":"FDA drug approval summary: Pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2008.01.001_bib253","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2005.06.006","article-title":"Radiation recall dermatitis with pemetrexed","volume":"50","author":"Hureaux","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib254","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.lungcan.2006.06.021","article-title":"Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis","volume":"54","author":"Barl\u00e9si","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib255","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.lungcan.2005.10.008","article-title":"Pemetrexed-associated urticarial vasculitis","volume":"51","author":"Lopes","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib256","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib257","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2165\/00003495-198937020-00005","article-title":"Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer","volume":"37","author":"Wagstaff","year":"1989","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2008.01.001_bib258","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.2002.20.4.1146","article-title":"Hypersensitivity reactions to oxaliplatin: Cross-reactivity to carboplatin and the introduction of a desensitization schedule","volume":"20","author":"Meyer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib259","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib260","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1398-9995.2005.00522.x","article-title":"Occupational rhinitis and asthma due to metal salts","volume":"60","author":"Malo","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2008.01.001_bib261","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0090-8258(03)00155-0","article-title":"Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity","volume":"89","author":"Markman","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib262","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2001.19.12.3126","article-title":"Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy","volume":"19","author":"Zanotti","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib263","first-page":"214","article-title":"Hypersensitivity reaction to carboplatin. Results of skin tests","volume":"20","author":"Menczer","year":"1999","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib264","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","article-title":"Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients","volume":"103","author":"Navo","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib265","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cncr.21168","article-title":"Successful carboplatin desensitization in patients with proven carboplatin allergy","volume":"104","author":"Confino-Cohen","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib266","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/030089160308900315","article-title":"Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases","volume":"89","author":"Libra","year":"2003","journal-title":"Tumori"},{"key":"10.1016\/j.jaad.2008.01.001_bib267","first-page":"3465","article-title":"Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma","volume":"23","author":"Ottaiano","year":"2003","journal-title":"Anticancer Res"},{"issue":"5 suppl. 15","key":"10.1016\/j.jaad.2008.01.001_bib268","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/sonc.2002.35524","article-title":"Oxaliplatin-related side effects: Characteristics and management","volume":"29","author":"Cassidy","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib269","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdg092","article-title":"Skin testing and hypersensitivity reactions to oxaliplatin","volume":"14","author":"Garufi","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib270","first-page":"75","article-title":"Anaphylaxis produced by oxaliplatin","volume":"15","author":"Gonzalez-Mahave","year":"2005","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaad.2008.01.001_bib271","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.ejca.2005.06.021","article-title":"Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients","volume":"41","author":"Maindrault-Goebel","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib272","first-page":"468","article-title":"Extravasation of Oxaliplatin (Eloxatin((R))) - Clinical Course","volume":"23","author":"Baur","year":"2000","journal-title":"Onkologie"},{"key":"10.1016\/j.jaad.2008.01.001_bib273","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdg252","article-title":"A case report of oxaliplatin extravasation","volume":"14","author":"Foo","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib274","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1191\/1078155205jp165oa","article-title":"Management of extravasation of oxaliplatin","volume":"11","author":"de Lemos","year":"2005","journal-title":"J Oncol Pharm Pract"},{"issue":"suppl 5","key":"10.1016\/j.jaad.2008.01.001_bib275","first-page":"29","article-title":"Necrotizing panniculitis after extravasation of oxaliplatin (abstract)","volume":"13","author":"Eckert","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib276","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0936-6555(02)00338-2","article-title":"Vesicant characteristics of oxaliplatin following antecubital extravasation","volume":"15","author":"Kennedy","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jaad.2008.01.001_bib277","first-page":"55","article-title":"Radiation recall with oxaliplatin: Report of a case and a review of the literature","volume":"13","author":"Chan","year":"2001","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jaad.2008.01.001_bib278","first-page":"851","article-title":"Delayed urticaria with oxaliplatin","volume":"24","author":"Petit-Laurent","year":"2000","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jaad.2008.01.001_bib279","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1016225024121","article-title":"A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: Tolerability and efficacy modification by liposomal encapsulation","volume":"20","author":"McMenemin","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2008.01.001_bib280","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.20207","article-title":"Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin?","volume":"100","author":"Theodoulou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib281","first-page":"6371","article-title":"Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies","volume":"50","author":"Gabizon","year":"1990","journal-title":"Cancer Res"},{"issue":"6 suppl. 13","key":"10.1016\/j.jaad.2008.01.001_bib282","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.seminoncol.2004.08.003","article-title":"Use of liposomal anthracyclines in Kaposi's sarcoma","volume":"31","author":"Krown","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib283","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib284","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002800050981","article-title":"Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia","volume":"44","author":"Lopez","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2008.01.001_bib285","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1081\/LPR-120004790","article-title":"Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: Experimental and clinical studies","volume":"12","author":"Szebeni","year":"2002","journal-title":"J Liposome Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib286","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00001813-200308000-00011","article-title":"Radiation recall dermatitis induced by pegylated liposomal doxorubicin","volume":"14","author":"Jimeno","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jaad.2008.01.001_bib287","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00001813-200401000-00006","article-title":"Re: \u2018Radiation recall dermatitis induced by pegylated liposomal doxorubicin.\u2019","volume":"15","author":"Muggia","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jaad.2008.01.001_bib288","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib289","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1592\/phco.20.15.1221.34593","article-title":"Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin","volume":"20","author":"Hui","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2008.01.001_bib290","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1006\/gyno.1995.1139","article-title":"Radiation recall reaction to idarubicin resulting in vaginal necrosis","volume":"57","author":"Gabel","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib291","first-page":"203","article-title":"Idarubicin-induced pigmentary changes of the nails","volume":"59","author":"Borecky","year":"1997","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2008.01.001_bib292","first-page":"3680","article-title":"Treatment of anthracycline extravasation with dexrazoxane","volume":"6","author":"Langer","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2008.01.001_bib293","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-5002(03)00039-4","article-title":"Treatment of relapsed small-cell lung cancer\u2014A focus on the evolving role of topotecan","volume":"40","author":"Rocha Lima","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2008.01.001_bib294","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14740338.4.1.45","article-title":"Toxicity of the topoisomerase I inhibitors","volume":"4","author":"Seiter","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2008.01.001_bib295","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/oxfordjournals.annonc.a059328","article-title":"Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group","volume":"6","author":"Creemers","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib296","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","article-title":"Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor","volume":"10","author":"Rowinsky","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2008.01.001_bib297","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/09546630252775234","article-title":"Neutrophilic eccrine hidradenitis secondary to topotecan","volume":"13","author":"Marini","year":"2002","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jaad.2008.01.001_bib298","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2133.1998.02389.x","article-title":"Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor","volume":"139","author":"Bachmeyer","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.01.001_bib299","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","article-title":"A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma","volume":"85","author":"Rothenberg","year":"1999","journal-title":"Cancer"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208000819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208000819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:09:12Z","timestamp":1759270152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962208000819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":299,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0190962208000819"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2008.01.001","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapeutic agents and the skin: An update","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2008.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}